论文信息 - A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 - 字舞流文

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

R. Guleria | S. Joshi | A. Trikha | M. Nadkar | S. Athalye | S. Loganathan | A. Marwah | Suresh Kumar | S. Vaidyanathan | R. de Souza | Subramanian Loganathan